Chenmei Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chenmei Liu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bin Yang
Dermatology Hospital of Southern Medical University Guangzhou Guangdong China
2 shared publications Aiqing Lin
Department of Dermatology Dermatology Hospital of Southern Medical University Guangzhou Guangdong China
1 shared publication- Changxing Li
Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication - Chao Yang
Dermatology Hospital Southern Medical University Guangzhou China
1 shared publication Dan Sun
Department of Dermatology Dermatology Hospital of Southern Medical University Guangzhou Guangdong China
1 shared publication- Freddy Gahimbare1 shared publication
Latest Publications
- Open Access
- 26 August 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71107
Oral Nintedanib for Refractory Generalized Keloids: A Prospective Exploratory Pilot Study
Background: Generalized keloids are severe, treatment‐refractory, disfiguring dermatoses that substantially impair physical and psychosocial well‐being and have limited effective systemic treatment options. Objective: To assess the short‐term safety, tolerability, and exploratory clinical outcomes of oral nintedanib in patients with refractory generalized keloids. Methods: In this single‐center, open‐label, assessor‐blinded exploratory pilot study, 10 adults with refractory generalized keloids received oral nintedanib 150 mg once daily or 150 mg twice daily for 8 weeks. The primary exploratory endpoint was change in Vancouver scar scale (VSS) score from baseline to Week 8. Secondary endpoints included pruritus and pain visual analogue scale (VAS) scores, patient and observer scar assessment scale (POSAS), dermatology life quality index (DLQI), imaging and histological assessments, and safety outcomes. Results: All participants completed treatment and follow‐up. Mean VSS scores decreased from 11.2 ± 1.3 to 8.2 ± 1.1 in the low‐dose group and from 10.4 ± 1.8 to 8.2 ± 1.9 in the high‐dose group. Pruritus severity and visible scar vascularity showed numerical improvements over 8 weeks, whereas POSAS and DLQI changed little. Histological assessment suggested reduced cellularity and more organized collagen architecture after treatment. No serious adverse events or treatment discontinuations occurred; the most common treatment‐related adverse events were mild diarrhea and transient transaminase elevation. Conclusion: In this small, uncontrolled exploratory pilot study, oral nintedanib was associated with early favorable changes in selected clinician‐rated and symptom‐based outcomes, whereas POSAS and DLQI showed limited short‐term change. These findings are preliminary and hypothesis‐generating and warrant confirmation in larger controlled studies with longer treatment and follow‐up.
- 26 August 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (9) , e71107
Open AccessOral Nintedanib for Refractory Generalized Keloids: A Prospective Exploratory Pilot Study
Background: Generalized keloids are severe, treatment‐refractory, disfiguring dermatoses that substantially impair physical and psychosocial well‐being and have limited effective systemic treatment options. Objective: To assess the short‐term safety, tolerability, and exploratory clinical outcomes of oral nintedanib in patients with refractory generalized keloids. Methods: In this single‐center, open‐label, assessor‐blinded exploratory pilot study, 10 adults with refractory generalized keloids received oral nintedanib 150 mg once daily or 150 mg twice daily for 8 weeks. The primary exploratory endpoint was change in Vancouver scar scale (VSS) score from baseline to Week 8. Secondary endpoints included pruritus and pain visual analogue scale (VAS) scores, patient and observer scar assessment scale (POSAS), dermatology life quality index (DLQI), imaging and histological assessments, and safety outcomes. Results: All participants completed treatment and follow‐up. Mean VSS scores decreased from 11.2 ± 1.3 to 8.2 ± 1.1 in the low‐dose group and from 10.4 ± 1.8 to 8.2 ± 1.9 in the high‐dose group. Pruritus severity and visible scar vascularity showed numerical improvements over 8 weeks, whereas POSAS and DLQI changed little. Histological assessment suggested reduced cellularity and more organized collagen architecture after treatment. No serious adverse events or treatment discontinuations occurred; the most common treatment‐related adverse events were mild diarrhea and transient transaminase elevation. Conclusion: In this small, uncontrolled exploratory pilot study, oral nintedanib was associated with early favorable changes in selected clinician‐rated and symptom‐based outcomes, whereas POSAS and DLQI showed limited short‐term change. These findings are preliminary and hypothesis‐generating and warrant confirmation in larger controlled studies with longer treatment and follow‐up.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Biologic Therapy for Refractory Pityriasis Rubra Pilaris
Background: Pityriasis rubra pilaris (PRP) is a rare, heterogeneous inflammatory dermatosis with no standardized treatment guidelines. Conventional therapies often fail to achieve sustained remission in refractory cases, particularly in the erythrodermic and pediatric subtypes. Biologics targeting tumor necrosis factor (TNF)‐α, interleukin (IL)‐17, and IL‐23 have been increasingly reported as off‐label treatment options. However, evidence remains fragmented, and consensus on treatment selection and sequencing for biologic nonresponders is lacking. Objective: To evaluate the real‐world clinical outcomes associated with biologic therapy in treatment‐resistant PRP via a retrospective case series and a scoping review of published evidence. Methods: Four patients with difficult‐to‐treat PRP (including one pediatric case) treated with biologic agents between 2022 and 2025 were included in the analysis. Clinical response was assessed by physician‐documented changes in erythema, scaling, and body surface area (BSA) involvement. A scoping review of PubMed, Embase, and the Cochrane Library (January 2015 to December 2025) was conducted in accordance with the PRISMA Extension for Scoping Reviews (PRISMA‐ScR) to identify English‐language clinical studies reporting on biologic therapy for PRP. Results: In this small retrospective series, all four patients showed clinical improvement during biologic therapy, with no serious adverse events observed. Three patients with suboptimal or incomplete responses to IL‐17A inhibitors underwent cross‐class switching to IL‐23 or IL‐12/23 inhibitors, followed by improved disease control. One pediatric patient responded well to IL‐17A inhibitor monotherapy. The scoping review included 76 clinical publications in the core evidence synthesis and 14 background or mechanistic publications retained for contextual discussion. Therapeutic responses to TNF‐α inhibitors, IL‐17 pathway inhibitors, IL‐12/23 inhibitors, and IL‐23 inhibitors were reported across PRP subtypes, although response durability, relapse, and loss of response varied across published reports. Conclusion: Biologic therapy was associated with meaningful clinical improvement in this small retrospective series of refractory PRP, and cross‐class biologic switching appeared feasible in selected patients with an inadequate initial response. These findings should be interpreted as preliminary and hypothesis‐generating. Larger prospective studies with standardized outcome measures are needed.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessBiologic Therapy for Refractory Pityriasis Rubra Pilaris
Background: Pityriasis rubra pilaris (PRP) is a rare, heterogeneous inflammatory dermatosis with no standardized treatment guidelines. Conventional therapies often fail to achieve sustained remission in refractory cases, particularly in the erythrodermic and pediatric subtypes. Biologics targeting tumor necrosis factor (TNF)‐α, interleukin (IL)‐17, and IL‐23 have been increasingly reported as off‐label treatment options. However, evidence remains fragmented, and consensus on treatment selection and sequencing for biologic nonresponders is lacking. Objective: To evaluate the real‐world clinical outcomes associated with biologic therapy in treatment‐resistant PRP via a retrospective case series and a scoping review of published evidence. Methods: Four patients with difficult‐to‐treat PRP (including one pediatric case) treated with biologic agents between 2022 and 2025 were included in the analysis. Clinical response was assessed by physician‐documented changes in erythema, scaling, and body surface area (BSA) involvement. A scoping review of PubMed, Embase, and the Cochrane Library (January 2015 to December 2025) was conducted in accordance with the PRISMA Extension for Scoping Reviews (PRISMA‐ScR) to identify English‐language clinical studies reporting on biologic therapy for PRP. Results: In this small retrospective series, all four patients showed clinical improvement during biologic therapy, with no serious adverse events observed. Three patients with suboptimal or incomplete responses to IL‐17A inhibitors underwent cross‐class switching to IL‐23 or IL‐12/23 inhibitors, followed by improved disease control. One pediatric patient responded well to IL‐17A inhibitor monotherapy. The scoping review included 76 clinical publications in the core evidence synthesis and 14 background or mechanistic publications retained for contextual discussion. Therapeutic responses to TNF‐α inhibitors, IL‐17 pathway inhibitors, IL‐12/23 inhibitors, and IL‐23 inhibitors were reported across PRP subtypes, although response durability, relapse, and loss of response varied across published reports. Conclusion: Biologic therapy was associated with meaningful clinical improvement in this small retrospective series of refractory PRP, and cross‐class biologic switching appeared feasible in selected patients with an inadequate initial response. These findings should be interpreted as preliminary and hypothesis‐generating. Larger prospective studies with standardized outcome measures are needed.
- 28 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1313-1317.e8
Variants in the Gene Encoding Filaggrin Cause Autosomal-Dominant Symmetrical Acral Keratoderma
- 28 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (7) , 1313-1317.e8
Variants in the Gene Encoding Filaggrin Cause Autosomal-Dominant Symmetrical Acral Keratoderma